)
Edge12 Dec 2025
Running on Clouds: The Story of On
The story of how a Swiss runner's pursuit of a new running sensation became On, aiming to be the most premium global sportswear brand worldwide.
Panbela Therapeutics
Panbela Therapeutics (PBLA) investor relations material
Panbela Therapeutics has been otc
Panbela Therapeutics Q3 2024 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2024 earnings summary14 Nov, 2024
Executive summary
Secured up to $12 million in strategic financing from Nant Capital, with $2.85 million funded and $9.15 million expected by November 15, 2024, supporting financial stability, clinical alliances, and potential immunotherapy collaborations.
Advanced multiple clinical programs, including the pivotal Phase III ASPIRE trial in metastatic pancreatic cancer, with full enrollment expected by Q2 2025 and interim analysis in Q1 2025.
Achieved milestones in the Flynpovi PACES trial for colorectal cancer prevention, with data readout anticipated in the second half of 2026.
Expanded research collaborations and preclinical programs, including partnerships with MD Anderson, Vanderbilt, and ImmunityBio, and initiated new trials in ovarian, lung, and STK11 mutant NSCLC.
Delisted from Nasdaq in April 2024; shares now quoted on OTCQB, with relisting application pending.
Financial highlights
Net loss for Q3 2024 was $7.2 million ($1.48 per diluted share), compared to $7.8 million ($53.74 per diluted share) in Q3 2023; net loss for the nine months ended September 30, 2024, was $21.4 million.
Research and development expenses were $6.0 million in Q3 2024, down from $6.7 million year-over-year; general and administrative expenses were flat at $1.1 million.
Cash as of September 30, 2024, was $142,000, not including the Nant Capital funding; cash position declined from $2.6 million at year-end 2023.
Total current assets were $5.2 million; current liabilities were $20.1 million at quarter end.
Cash used in operations for the nine months ended September 30, 2024, was $12.5 million.
Outlook and guidance
Interim analysis for the ASPIRE trial is expected in Q1 2025, with full enrollment by Q2 2025.
Data readout for the PACES trial is anticipated in the second half of 2026.
Phase II ovarian and neoadjuvant pancreatic cancer trials are planned to open in early 2025.
Company expects to continue incurring substantial losses and negative cash flows as it advances clinical programs.
Additional capital is required immediately to fund operations and complete clinical trials; no assurance of obtaining financing.
How long will Nant Capital funds extend runway?
What does ASPIRE's lower event rate imply?
Explain the strategic value of Nant Capital alliance
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Panbela Therapeutics
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Panbela Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for the treatment of cancer. The company's lead programs target pancreatic cancer and other gastrointestinal cancers, with an emphasis on inhibiting tumor growth and improving patient outcomes. Panbela’s approach involves advancing small-molecule therapeutics that address significant unmet medical needs in oncology, aiming to provide more effective treatment options for aggressive cancers. The company is headquartered in Waconia, Minnesota, USA, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage